50 Key Biopharmaceutical and Biotechnology Companies is a comprehensive look at the top 50 companies that are shaping the biotherapeutics market in 2017 and beyond. The top 50 companies in this report were chosen for a variety of reasons, including sales of marketed biopharmaceutical products, innovation in biotherapeutics, and unique additions to the market, either marketed products or products in development.
50 Key Biopharmaceutical and Biotechnology Companies
includes large traditional pharma powerhouses such as Pfizer, Novartis, Roche, Merck, GSK, Bristol-Myers Squibb, Bayer, and others; but it also includes smaller niche companies such as Genmab, Seattle Genetics, etc. In addition, it includes leading biopharmaceuticals such as Amgen and Biogen, and leading biotech companies such as Qiagen, Alexion, Agilent, Waters Co and others.
Biopharmaceuticals are therapeutic agents intended to treat symptoms and/or underlying causes of a variety of disorders and diseases. They have been a growing part of the pharmaceutical landscape since the early 1980s and is, today, one of the fastest growing areas in the pharmaceutical industry, growing at an average rate of 12%-15% over the past two years.
Today, there are many biologics in the approval pipeline and it has been projected that over 65% of drugs approved for the marketplace in 2017 will be the result of biotechnology. Biopharmaceuticals hold great promise for treating some of the most intractable medical conditions such as cancer and autoimmune disease.
50 Key Biopharmaceutical and Biotechnology Companies profiles these market leaders in-depth, presenting detailed information about each company, including:
Selected Biopharmaceutical Products
Biopharmaceuticals in Development
Selected Corporate Developments
Regional Revenue Breakdown by Percentage (%)
Key Topics Covered:
1: Executive Summary Introduction Scope and Methodology Market Summary
2: Introduction Biopharmaceuticals and Biotherapeutics Biopharmaceuticals Biotechnology Areas Of Treatment For Biopharmaceuticals Regulations For Biopharmaceuticals
3: 50 Key Biopharmaceutical and Biotechnology Companies: Profiles